Comprehensive peptidomimetic libraries targeting protein-protein interactions.

Transient protein-protein interactions (PPIs) are essential components in cellular signaling pathways as well as in important processes such as viral infection, replication, and immune suppression. The unknown or uncharacterized PPIs involved in such interaction networks often represent compelling therapeutic targets for drug discovery. To date, however, the main strategies for discovery of small molecule modulators of PPIs are typically limited to structurally characterized targets. Recent developments in molecular scaffolds that mimic the side chain display of peptide secondary structures have yielded effective designs, but few screening libraries of such mimetics are available to interrogate PPI targets. We initiated a program to prepare a comprehensive small molecule library designed to mimic the three major recognition motifs that mediate PPIs (α-helix, β-turn, and β-strand). Three libraries would be built around templates designed to mimic each such secondary structure and substituted with all triplet combinations of groups representing the 20 natural amino acid side chains. When combined, the three libraries would contain a member capable of mimicking the key interaction and recognition residues of most targetable PPIs. In this Account, we summarize the results of the design, synthesis, and validation of an 8000 member α-helix mimetic library and a 4200 member β-turn mimetic library. We expect that the screening of these libraries will not only provide lead structures against α-helix- or β-turn-mediated protein-protein or peptide-receptor interactions, even if the nature of the interaction is unknown, but also yield key insights into the recognition motif (α-helix or β-turn) and identify the key residues mediating the interaction. Consistent with this expectation, the screening of the libraries against p53/MDM2 and HIV-1 gp41 (α-helix mimetic library) or the opioid receptors (β-turn mimetic library) led to the discovery of library members expected to mimic the known endogenous ligands. These efforts led to the discovery of high-affinity α-helix mimetics (K(i) = 0.7 μM) against HIV-1 gp41 as well as high-affinity and selective β-turn mimetics (K(i) = 80 nM) against the κ-opioid receptor. The results suggest that the use of such comprehensive libraries of peptide secondary structure mimetics, built around effective molecular scaffolds, constitutes a powerful method of interrogating PPIs. These structures provide small molecule modulators of PPI networks for therapeutic target validation, lead compound discovery, and the identification of modulators of biological processes for further study.

[1]  M. Eguchi.  Recent advances in selective opioid receptor agonists and antagonists , 2004, Medicinal research reviews.

[2]  Shibo Jiang,et al.  Development of Peptide and Small‐Molecule HIV‐1 Fusion Inhibitors that Target gp41 , 2010, ChemMedChem.

[3]  Min Lu,et al.  Structural and biological mimicry of protein surface recognition by α/β-peptide foldamers , 2009, Proceedings of the National Academy of Sciences.

[4]  A. Hamilton,et al.  Protein Secondary Structure Mimetics as Modulators of Protein–Protein and Protein‐Ligand Interactions , 2008 .

[5]  Landon R. Whitby,et al.  Discovery of HIV fusion inhibitors targeting gp41 using a comprehensive α-helix mimetic library. , 2012, Bioorganic & medicinal chemistry letters.

[6]  J. P. Shea,et al.  Design, synthesis, and evaluation of opioid analogues with non-peptidic beta-turn scaffold: enkephalin and endomorphin mimetics. , 2002, Journal of medicinal chemistry.

[7]  D. Fairlie,et al.  Update 1 of: Over one hundred peptide-activated G protein-coupled receptors recognize ligands with turn structure. , 2010, Chemical reviews.

[8]  Dale L Boger,et al.  Solution-phase combinatorial libraries: modulating cellular signaling by targeting protein-protein or protein-DNA interactions. , 2003, Angewandte Chemie.

[9]  D. Boger,et al.  Trifluoromethyl ketone inhibitors of fatty acid amide hydrolase: a probe of structural and conformational features contributing to inhibition. , 1999, Bioorganic & medicinal chemistry letters.

[10]  Kevin Burgess,et al.  Minimalist and universal peptidomimetics. , 2011, Chemical Society reviews.

[11]  G. Mustata,et al.  Discovery of modulators of protein-protein interactions: current approaches and limitations. , 2011, Current topics in medicinal chemistry.

[12]  Jorge Becerril,et al.  Design and application of an alpha-helix-mimetic scaffold based on an oligoamide-foldamer strategy: antagonism of the Bak BH3/Bcl-xL complex. , 2003, Angewandte Chemie.

[13]  Bryan L. Roth,et al.  Design, synthesis, and validation of a β-turn mimetic library targeting protein-protein and peptide-receptor interactions. , 2011, Journal of the American Chemical Society.

[14]  M. Gochin,et al.  A Novel Fluorescence Intensity Screening Assay Identifies New Low-Molecular-Weight Inhibitors of the gp41 Coiled-Coil Domain of Human Immunodeficiency Virus Type 1 , 2007, Antimicrobial Agents and Chemotherapy.

[15]  D. Boger,et al.  α-Ketoheterocycle-based Inhibitors of Fatty Acid Amide Hydrolase (FAAH). , 2012, ACS chemical neuroscience.

[16]  Bernhard Pfeiffer,et al.  Over One Hundred Peptide‐Activated G Protein‐Coupled Receptors Recognize Ligands with Turn Structure , 2005 .

[17]  P S Kim,et al.  Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[18]  D. Boger,et al.  A solution-phase strategy for the synthesis of chemical libraries containing small organic molecules: a universal and dipeptide mimetic template. , 1996, Bioorganic & medicinal chemistry.

[19]  Michelle R. Arkin,et al.  Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.

[20]  P. S. Kim,et al.  HIV Entry and Its Inhibition , 1998, Cell.

[21]  Laurie E. Grove,et al.  Structural conservation of druggable hot spots in protein–protein interfaces , 2011, Proceedings of the National Academy of Sciences.

[22]  D. Boger,et al.  Novel Solution Phase Strategy for the Synthesis of Chemical Libraries Containing Small Organic Molecules. , 1996 .

[23]  Michael Hedrick,et al.  Total Synthesis of Distamycin A and 2640 Analogues: A Solution-Phase Combinatorial Approach to the Discovery of New, Bioactive DNA Binding Agents and Development of a Rapid, High-Throughput Screen for Determining Relative DNA Binding Affinity or DNA Binding Sequence Selectivity , 2000 .

[24]  Sukwon Hong,et al.  Design, synthesis, and evaluation of an alpha-helix mimetic library targeting protein-protein interactions. , 2009, Journal of the American Chemical Society.

[25]  D. Boger,et al.  Discovery of inhibitors of aberrant gene transcription from Libraries of DNA binding molecules: inhibition of LEF-1-mediated gene transcription and oncogenic transformation. , 2009, Journal of the American Chemical Society.

[26]  Michael S. Kay,et al.  Inhibiting HIV Fusion with a β-Peptide Foldamer , 2005 .

[27]  Jeffrey P. Plante,et al.  Oligobenzamide proteomimetic inhibitors of the p53–hDM2 protein–protein interaction , 2009, Chemical communications.

[28]  D. Boger,et al.  Generalized Dipeptidomimetic Template: Solution Phase Parallel Synthesis of Combinatorial Libraries , 1996 .

[29]  Shibo Jiang,et al.  Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusion. , 2002, Angewandte Chemie.

[30]  Pedro A Fernandes,et al.  Hot spots—A review of the protein–protein interface determinant amino‐acid residues , 2007, Proteins.

[31]  Shaomeng Wang,et al.  Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. , 2009, Annual review of pharmacology and toxicology.

[32]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[33]  D. Boger,et al.  A simple, high-resolution method for establishing DNA binding affinity and sequence selectivity. , 2001, Journal of the American Chemical Society.

[34]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[35]  Landon R. Whitby,et al.  Small molecule peptidomimetic inhibitors of importin α/β mediated nuclear transport. , 2010, Bioorganic & medicinal chemistry.

[36]  Brooke N. Bullock,et al.  Assessing helical protein interfaces for inhibitor design. , 2011, Journal of the American Chemical Society.

[37]  Tae-Kyung Lee,et al.  Solid-phase synthesis of tris-benzamides as α-helix mimetics. , 2011, ACS combinatorial science.

[38]  P. Aloy,et al.  A network medicine approach to human disease , 2009, FEBS letters.

[39]  Jakub Fichna,et al.  The Endomorphin System and Its Evolving Neurophysiological Role , 2007, Pharmacological Reviews.

[40]  A. May,et al.  The critical protein interactions and structures that elicit growth deregulation in cancer and viral replication , 2011, Wiley interdisciplinary reviews. Systems biology and medicine.

[41]  Philip M. Dean,et al.  Design criteria for molecular mimics of fragments of the β-turn. 1. Cα atom analysis , 1999, J. Comput. Aided Mol. Des..